MAP3K8 anticorps (AA 1-300)

N° du produit ABIN7160057

Détail du produit anti-MAP3K8 anticorps

Antigène: MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))

Épitope: AA 1-300

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MAP3K8 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Mitogen-activated protein kinase kinase kinase 8 protein (1-300AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur MAP3K8

Antigène: MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))

Autre désignation: MAP3K8 (MAP3K8 Produits)

Synonymes: anticorps MAP3K8, anticorps COT, anticorps EST, anticorps ESTF, anticorps MEKK8, anticorps TPL2, anticorps Tpl-2, anticorps c-COT, anticorps Cot, anticorps Cot/Tpl2, anticorps Est, anticorps Estf, anticorps Tpl2, anticorps D17TPL2, anticorps mitogen-activated protein kinase kinase kinase 8, anticorps MAP3K8, anticorps map3k8, anticorps Map3k8

Sujet:

Background: Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.

Aliases: AURA2 antibody, c COT antibody, Cancer Osaka thyroid oncogene antibody, CCOT antibody, COT antibody, COT proto oncogene serine/threonine protein kinase antibody, EST antibody, ESTF antibody, Ewing sarcoma transformant antibody, FLJ10486 antibody, M3K8_HUMAN antibody, MAP3K 8 antibody, MAP3K8 antibody, MEKK8 antibody, Mitogen activated protein kinase kinase kinase 8 antibody, Mitogen-activated protein kinase kinase kinase 8 antibody, Proto oncogene cCot antibody, Proto-oncogene c-Cot antibody, Serine/threonine protein kinase cot antibody, Serine/threonine-protein kinase cot antibody, TPL 2 antibody, TPL-2 antibody, TPL2 antibody, Tumor progression locus 2 antibody

UniProt: P41279

Pathways: Signalisation PI3K-Akt, TCR Signaling